A
128.09
as on 23 May 2025 at 15:59
Market Cap
₹3,394 Cr
PE Ratio
60.00
ROCE
44.35%
Today Avantel opened at 129.08 while its previous close was at 128.76. In todays trading session AVANTEL reached a high of 132.00 and low of 127.50. The average traded price for today is 129.19. The 50 DMA stands at 2.32 and 200 DMA is at 2.32. Looking at intraday trend, the stock is moving sideways.
Get 10+ Layouts, 100+ Indicators, Custom Timeframes & All Drawing Tools for FREE.
High
132.00
Low
127.50
Open at
129.08
Prev Close
128.76
Volumes
9,99,418
Avg Price
129.19
Lower Circuit
102.47
Upper Circuit
153.70
Quantity
100
Time
15:59:54
3 M High
139.60
3 M Low
97.13
1 Yr High
200.91
1 Yr Low
95.13
3 Yr High
200.91
3 Yr Low
95.13
5 Yr High
200.91
5 Yr Low
95.13
Life Insurance Corporation of India: Sets Guinness World Record for Most Life Insurance Policies Sold in 24 Hours
LIC achieved a Guinness World Record on January 20, 2025, by selling 5,88,107 life insurance policies in 24 hours through 4,52,839 agents across India. This initiative, called 'Mad Million Day', was spearheaded by LIC MD and CEO Siddhartha Mohanty.
Sun Pharmaceutical Industries Ltd: Targets Mid-To-High Single-Digit Growth for FY26
Sun Pharma aims for mid-to-high single-digit revenue growth in FY26, considering US regulatory uncertainties. The company awaits clarity on tariffs and MFN drug pricing policy impact. Halol facility is ready for FDA audit, while Mohali remediation is ongoing. Two new products, Leqselvi and Unloxcyt, are planned for FY26 launch. Specialty sales increased 17.1% YoY to $1.216 billion in FY25. US generics business faces competitive pricing environment.
Metro Brands: Targeting 12-15% Long-Term Revenue CAGR
Metro Brands aims for 12-15% long-term revenue CAGR. E-commerce sales grew 45% in Q4, contributing over 10% to total revenue. The company added 18 new stores and closed 5 in Q4, reaching 908 stores. CEO emphasizes profitability-driven expansion amid rising retail rents.
Zydus Lifesciences: FDA Approves Generic Severe Acne Treatment
Zydus Lifesciences received FDA approval for isotretinoin capsules in six dosage strengths, a generic version of Absorica for severe nodular acne. The US market for this drug is estimated at $115.4 million annually. Zydus now has 427 final FDA approvals.
Strides Pharma Science: Confident in US Growth, Maintains $400 Million FY28 Sales Target
Strides Pharma Science expects continued growth in FY26, targeting $400 million in US sales by FY27-28. The company plans to leverage its 260 ANDAs, with only 70 commercialized so far. Strides is also shifting towards complex products and specialty offerings. The company reduced its debt-to-EBITDA ratio to under 1.9 times and aims for 20% margins in FY26.
Piccadily Agro Industries: Launches Luxury Vodka 'Cashmir'
Piccadily Agro Industries Limited, known for Indri-Trini single malt and Camikara rum, has introduced Cashmir, a premium vodka made from organic Indian winter wheat and Kashmir Valley glacial waters. Priced between ₹1500-₹2000, it will be available in select Indian cities and international markets.
Ola Electric: Roadster X Deliveries Begin After Two-Month Delay
Ola Electric has started delivering its Roadster X motorcycle after a two-month delay. The homologation certificate arrived just hours before the first deliveries on Friday. The delay raised questions about the vehicle's roadworthiness and led to discrepancies in February's sales data reporting.
Tata Power Company Ltd: Morgan Stanley Raises Target Price, Reiterates 'Overweight' Rating
Morgan Stanley raises Tata Power's target price to ₹449 from ₹425, implying 13% upside. Expects steady growth despite RE project delays. Forecasts EBITDA and PAT CAGRs of 15% and 14% over FY25-FY28. Green energy segment projected to contribute 58% of EBITDA by FY28. Net debt-to-EBITDA expected to peak at 3.6x.
Close Price
Volume
AVANTEL share price in last 10 trading sessions
Market Cap (₹ Cr.)
3,394
PE Ratio
60.00
PB Ratio
10.65
Dividend Yield
0.14%
ROE
32.02%
ROCE
44.35%
Book Value (₹)
12.01
Face Value (₹)
2.00
Held By | Jun 2024 | Jul 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
---|---|---|---|---|---|
Promoters | 40.06% | 40.06% | 40.06% | 38.58% | 38.57% |
Domestic Institutional Investors (DII) | 0.39% | 0.41% | 0.65% | 0.92% | 0.42% |
Foreign Institutional Investors (FII) | 0.01% | 0.00% | 0.11% | 0.18% | 0.48% |
Public Investors | 49.22% | 49.14% | 49.15% | 50.28% | 50.65% |
Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Promoters
Domestic Institutional Investors (DII)
Foreign Institutional Investors (FII)
Public Investors
Government
1 Week
1 Month
3 Months
6 Months
9 Months
1 Year
2 Years
3 Years
4 Years
5 Years
1 Week
1 Month
3 Months
6 Months
9 Months
Create Wealth in Longterm with Weekly and Monthly SIP in Stocks.
Period | Simple | Signal |
---|---|---|
5-SMA | 2.86 | Bearish |
10-SMA | 2.98 | Bearish |
20-SMA | 2.84 | Bearish |
50-SMA | 2.32 | Bullish |
100-SMA | 2.42 | Bullish |
200-SMA | 2.32 | Bullish |
Indicator | Value | Action |
---|---|---|
RSI(14) | 51.07 | Neutral |
ATR(14) | 0.19 | Volatile |
STOCH(9,6) | 33.21 | Neutral |
STOCH RSI(14) | -0.00 | Oversold |
MACD(12,26) | -0.06 | Bearish |
ADX(14) | 39.02 | Strong Trend |
Summary of Technical Indicators for AVANTEL
In Crores
In Crores
In Crores
In Crores
Get In-depth View of AVANTEL Quaterly Results, Balance Sheet, Cashflows & Corporate Action.
All values are in Crores
Revenue
Profit
Loss
Life Insurance Corporation of India: Sets Guinness World Record for Most Life Insurance Policies Sold in 24 Hours
LIC achieved a Guinness World Record on January 20, 2025, by selling 5,88,107 life insurance policies in 24 hours through 4,52,839 agents across India. This initiative, called 'Mad Million Day', was spearheaded by LIC MD and CEO Siddhartha Mohanty.
860.25
Sun Pharmaceutical Industries Ltd: Targets Mid-To-High Single-Digit Growth for FY26
Sun Pharma aims for mid-to-high single-digit revenue growth in FY26, considering US regulatory uncertainties. The company awaits clarity on tariffs and MFN drug pricing policy impact. Halol facility is ready for FDA audit, while Mohali remediation is ongoing. Two new products, Leqselvi and Unloxcyt, are planned for FY26 launch. Specialty sales increased 17.1% YoY to $1.216 billion in FY25. US generics business faces competitive pricing environment.
1,683.60
Metro Brands: Targeting 12-15% Long-Term Revenue CAGR
Metro Brands aims for 12-15% long-term revenue CAGR. E-commerce sales grew 45% in Q4, contributing over 10% to total revenue. The company added 18 new stores and closed 5 in Q4, reaching 908 stores. CEO emphasizes profitability-driven expansion amid rising retail rents.
1,210.60
Zydus Lifesciences: FDA Approves Generic Severe Acne Treatment
Zydus Lifesciences received FDA approval for isotretinoin capsules in six dosage strengths, a generic version of Absorica for severe nodular acne. The US market for this drug is estimated at $115.4 million annually. Zydus now has 427 final FDA approvals.
908.60
Strides Pharma Science: Confident in US Growth, Maintains $400 Million FY28 Sales Target
Strides Pharma Science expects continued growth in FY26, targeting $400 million in US sales by FY27-28. The company plans to leverage its 260 ANDAs, with only 70 commercialized so far. Strides is also shifting towards complex products and specialty offerings. The company reduced its debt-to-EBITDA ratio to under 1.9 times and aims for 20% margins in FY26.
731.65
Piccadily Agro Industries: Launches Luxury Vodka 'Cashmir'
Piccadily Agro Industries Limited, known for Indri-Trini single malt and Camikara rum, has introduced Cashmir, a premium vodka made from organic Indian winter wheat and Kashmir Valley glacial waters. Priced between ₹1500-₹2000, it will be available in select Indian cities and international markets.
Ola Electric: Roadster X Deliveries Begin After Two-Month Delay
Ola Electric has started delivering its Roadster X motorcycle after a two-month delay. The homologation certificate arrived just hours before the first deliveries on Friday. The delay raised questions about the vehicle's roadworthiness and led to discrepancies in February's sales data reporting.
52.91
Tata Power Company Ltd: Morgan Stanley Raises Target Price, Reiterates 'Overweight' Rating
Morgan Stanley raises Tata Power's target price to ₹449 from ₹425, implying 13% upside. Expects steady growth despite RE project delays. Forecasts EBITDA and PAT CAGRs of 15% and 14% over FY25-FY28. Green energy segment projected to contribute 58% of EBITDA by FY28. Net debt-to-EBITDA expected to peak at 3.6x.
402.05
Pay Zero Brokerage on Delivery
Open FREE Demat Account
+91
Or Scan the QR Code to download the Dhan App
Explore | Sitemap
*All securities mentioned on this website are exemplary and not recommendatory.
*Current prices on the website are delayed by 15 mins, login to check live prices.
We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.
Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.
That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.
©2021-2025 Moneylicious Securities Private Limited. All rights reserved. CIN: U74999MH2012PTC433549 Moneylicious Securities is part of Raise Financial Services.
In case of grievances for any of the services rendered by Moneylicious Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.
Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.
DHAN is a brand owned by Moneylicious Securities Private Limited. All DHAN clients are registered under Moneylicious Securities Private Limited. Clients are advised to refer to our company as Moneylicious Securities Private Limited when communicating with regulatory authorities.
Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances
Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit
Attention investors:
Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / Moneylicious / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.
Moneylicious Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account.
Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/
Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX
Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets